QXAS yields 25.02% · ABBV yields 3.09%● Live data
📍 ABBV pulled ahead of the other in Year 10
Combined, QXAS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QXAS + ABBV for your $10,000?
QXAS seeks 2x daily exposure to the largest crypto assets, excluding Bitcoin (BTC), stablecoins, and memecoins. It does not hold crypto directly, but gains exposure via swaps, options, futures contracts, or ETPs, targeting up to 10 crypto assets traded in US exchanges. The fund uses options contracts for leveraged exposure, allowing dynamic adjustments based on market conditions, liquidity, or pricing. The fund buys standardized, cash-settled futures to manage contango and backwardation and invests in ETPs for long exposure. The fund holds cash and cash-like instruments as collateral and may enter reverse repurchase agreements. Up to 25% of assets may be invested through a wholly owned Cayman Islands subsidiary. The market cap-weighted portfolio is reviewed and rebalanced at least monthly, capping each asset at 50%. The actively managed fund has full discretion to adjust at any time. Daily leverage resets may cause long-term returns to differ from the underlying assets.
Full QXAS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.